Track GlaxoSmithKline Pharmaceuticals Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

GlaxoSmithKline Pharmaceuticals Limited GLAXO.NS · Stock Open GlaxoSmithKline Pharmaceuticals Limited in new tab

2672.60 INR
P/E
40.07
EPS
67.68
Yield
2.14%
Safety Score
17
P/B
24.42
ROE
63.90
Beta
0.17
Target Price
3053.50 INR
Loading chart...
Key Metrics
Earnings dateFeb. 15, 2027
P/E40.07
EPS67.68
Book Value111.06
Price to Book24.42
Debt/Equity2.09
% Insiders75.657%
Growth
Revenue Growth0.21%
Earnings Growth0.31%
Estimates
Forward P/E34.27
Forward EPS79.15
Target Mean Price3053.50
Dividend
Dividend Yield2.14%
Annual dividends57.00 INR
Ex-Div. DateMay 29, 2026
5y avg Yield1.79%

DCF valuation

Model fair value for GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
Result
Sign in to run the valuation for GLAXO.NS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 3053.50 INR (low 2760.00, high 3500.00) · as of 11 Nov 2026
Low 2760.00
Mean 3053.50
High 3500.00
Price 2672.60
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

GlaxoSmithKline Pharmaceuticals Limited Logo GlaxoSmithKline Pharmaceuticals Limited Analysis (GLAXO.NS)

India Health Care Official Website Stock

Is GlaxoSmithKline Pharmaceuticals Limited a good investment? GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) is currently trading at 2672.60 INR. Market analysts have a consensus price target of 3053.50 INR. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 40.07. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: GlaxoSmithKline Pharmaceuticals Limited is expected to release its next earnings report on Feb. 15, 2027. The market consensus estimate for Forward EPS is 79.15.

For income investors, GlaxoSmithKline Pharmaceuticals Limited pays a dividend yield of 2.14%.

Investor FAQ

Does GlaxoSmithKline Pharmaceuticals Limited pay a dividend?

Yes, it pays an annual dividend of 57.00 INR (2.14% yield).

What asset class is GlaxoSmithKline Pharmaceuticals Limited?

GlaxoSmithKline Pharmaceuticals Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 15, 2027. The company currently has a trailing EPS of 67.68.

Company Profile

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

Exchange Ticker
NSI (India) GLAXO.NS
Trades
Dividend Yield
2.14%
5y avg 1.79%
Annual Dividends
57.00INR
Next Ex. Div Date
May 29, 2026
Dividend History paid per year (INR)
Historical Dividends
Year Total Dividends
▸2027
57.00 INR
July 2, 2027 (estimated) 57.0000
▸2026
57.00 INR
July 2, 2026 57.0000
▸2025
42.00 INR
June 30, 2025 42.0000
▸2024
44.00 INR
Nov. 12, 2024 12.0000
July 28, 2024 32.0000
▸2023
32.00 INR
Aug. 25, 2023 32.0000
▸2022
180.00 INR
Aug. 25, 2022 60.0000
Aug. 25, 2022 30.0000
Aug. 25, 2022 90.0000
▸2021
30.00 INR
Aug. 26, 2021 30.0000
▸2020
20.00 INR
Aug. 26, 2020 20.0000
▸2019
20.00 INR
Aug. 21, 2019 20.0000
▸2018
35.00 INR
Aug. 23, 2018 35.0000
▸2017
30.00 INR
Aug. 24, 2017 30.0000
▸2016
50.00 INR
Aug. 27, 2016 50.0000
▸2015
62.50 INR
Aug. 30, 2015 62.5000
▸2014
50.00 INR
May 17, 2014 50.0000
▸2013
50.00 INR
April 17, 2013 50.0000
▸2012
45.00 INR
April 11, 2012 45.0000
▸2011
40.00 INR
March 30, 2011 40.0000
▸2010
30.00 INR
April 24, 2010 30.0000
▸2009
58.00 INR
April 2, 2009 58.0000
▸2008
36.00 INR
April 21, 2008 36.0000
▸2007
31.00 INR
March 30, 2007 31.0000
▸2006
28.00 INR
April 12, 2006 28.0000
▸2005
24.00 INR
March 30, 2005 24.0000
▸2004
10.00 INR
March 13, 2004 10.0000
▸2003
7.00 INR
May 2, 2003 7.0000
Upcoming Dividends
Name Payment Date Status Amount
GlaxoSmithKline Pharmaceuticals Limited Jul 02, 2026 57.0 INR
Stock Splits
Split Date Split Ratio to 1
Sept. 11, 2018 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion